ClinicalTrials.gg
CompletedNCT03435081BREEZE-AD5Updated Sep 9, 2022Results posted

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Baricitinib and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 81 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-09.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.

Enrollment
6th of 11
440 · median 440
Started
2018
with 4 others
Phase 3
8 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
9 of 11
Eli Lilly and Company

Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 6th largest by enrollment, is one of 5 that started in 2018, is one of 8 in phase 3, and was the 6th registered.

Dermatitis, Atopic

1,592 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing baricitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • atopic eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.
  • Have moderate to severe AD, including all of the following:

    • EASI score ≥16
    • IGA score of ≥3
    • ≥10% of BSA involvement
  • Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a ).
  • Agree to use emollients daily.

Exclusion criteria

Exclusion Criteria:

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, , or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:

    • monoclonal antibody for less than 5 half-lives before randomization
    • received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks before randomization
    • received any parenteral corticosteroid administered by intramuscular or intravenous injection within 6 weeks of planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
    • have had an intra-articular corticosteroid injection within 6 weeks of planned randomization
    • probenecid at the time of randomization that cannot be discontinued for the duration of the study
  • Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or Stage III/IV heart failure.
  • Have a history of venous thromboembolic event (VTE), or are considered at high risk for VTE.
  • Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
  • Have specific laboratory abnormalities.
  • Have received certain treatments that are .
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    2 milligram (mg) Baricitinib

    2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    1 mg Baricitinib

    1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.

    Drug: Baricitinib · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo administered orally every day.

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 16

  2. Percentage of Participants Achieving EASI75 (1 mg Baricitinib)

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 16

  3. Percentage of Participants Achieving EASI90

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

    Time frame: Week 16

  4. Percent Change From Baseline in EASI Score

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Squares (LS) Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  5. Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

    Time frame: Week 16

  6. Percentage of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS)

    The Itch NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

    Time frame: 16 Weeks

  7. Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)

    Atopic Dermatitis Sleep Scale (ADSS) is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep, frequency of waking, and difficulty getting back to sleep last night. Item 2, frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  8. Change From Baseline in Skin Pain NRS

    Skin Pain NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  9. Percentage of of Participants Achieving EASI50

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a ≥ 50% improvement from baseline in EASI score.

    Time frame: Week 16

  10. Percentage of Participants Achieving IGA of 0

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 16

  11. Change From Baseline in SCORAD

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit and treatment-by-visit interaction as fixed categorial effects and baseline and baseline-by-visit interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  12. Percentage of Participants Achieving SCORAD90

    The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. SCORAD90 is defined as a ≥ 90% improvement from baseline in the SCORAD score.

    Time frame: Week 16

  13. Change From Baseline in Body Surface Area (BSA) Affected

    Body surface area affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

    Time frame: Baseline, Week 16

  14. Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

    Percentage of participants developing skin infections requiring antibiotic treatment.

    Time frame: Week 16

  15. Percent Change From Baseline in Itch NRS

    The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA),and treatment-by-visit-interaction as fixed categorical effects and baseline, and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  16. Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)

    The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  17. Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score

    The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  18. Change From Baseline on the Hospital Anxiety Depression Scale (HADS)

    The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  19. Change From Baseline on the Dermatology Life Quality Index (DLQI)

    The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered or "not relevant" responses scored as "0." Scores range from 0 to 30 ("no impact on participant's life" to "extremely large effect on participant's life"), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA),visit, and treatment-by-visit-interaction as fixed categorical and baseline, and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  20. Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire

    The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LS Mean were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

    Time frame: Baseline, Week 16

  21. Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Index Score United States (US) and United Kingdom (UK) Algorithm

    The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the UK algorithm, with scores ranging from -0.594 to 1, and the US algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Means were calculated using a MMRM model with treatment, baseline disease activity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

    Time frame: Baseline, Week 16

  22. Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)

    EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranges from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Means were calculated using a MMRM model with treatment, baseline disease activity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

    Time frame: Baseline, Week 16

  23. Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement

    The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Week 4

07

Results

Posted Jan 25, 2021

Participant flow

Week 0 to Week 16
Participant flow — Week 0 to Week 16
MilestonePlacebo1 Milligram (mg) Baricitinib2 mg Baricitinib
Started147147146
Received at least one dose of study drug147147146
Completed week 16 and entered jaix study11111296
Completed126131127
Not completed211619
Withdrew: Lack of efficacy650
Withdrew: Adverse event222
Withdrew: Withdrawal by subject8710
Withdrew: Lost to follow-up314
Withdrew: Pregnancy100
Withdrew: Non-compliance102
Withdrew: Inadequate response010
Withdrew: Withdrawal due to caregiver circumstance001
Week 16 to Week 104
Participant flow — Week 16 to Week 104
MilestonePlacebo1 Milligram (mg) Baricitinib2 mg Baricitinib
Started81935
Rolled over into the open-label extension study jaix.61419
Completed5616
Not completed31319
Withdrew: Lack of efficacy21110
Withdrew: Adverse event102
Withdrew: Withdrawal by subject012
Withdrew: Lost to follow-up014
Withdrew: Non--compliance001

Outcome measures

PrimaryPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib)
percentage of participantsPlacebo2 mg Baricitinib
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib)8.2 (4.7 to 13.7)29.5 (22.7 to 37.3)
Statistical analysis
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.60 · 95% CI 2.31 to 9.15
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement5.4 (2.8 to 10.4)12.9 (8.4 to 19.3)24.0 (17.8 to 31.5)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.033 · Odds ratio (or): 2.51 · 95% CI 1.08 to 5.83
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.29 · 95% CI 2.40 to 11.68
SecondaryPercentage of Participants Achieving EASI75 (1 mg Baricitinib)

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI75 (1 mg Baricitinib)
percentage of participantsPlacebo1 mg Baricitinib
Percentage of Participants Achieving EASI75 (1 mg Baricitinib)8.2 (4.7 to 13.7)12.9 (8.4 to 19.3)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.167 · Odds ratio (or): 1.71 · 95% CI 0.80 to 3.63
SecondaryPercentage of Participants Achieving EASI90

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving EASI90
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving EASI903.4 (1.5 to 7.7)7.5 (4.2 to 12.9)20.5 (14.8 to 27.8)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.131 · Odds ratio (or): 2.23 · 95% CI 0.79 to 6.31
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.73 · 95% CI 2.63 to 17.19
SecondaryPercent Change From Baseline in EASI Score

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Squares (LS) Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in EASI Score
percent changePlacebo1 mg Baricitinib2 mg Baricitinib
Percent Change From Baseline in EASI Score-34.07 ± 5.529-46.66 ± 4.469-54.37 ± 4.156
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.077 · Mean difference (final values): -12.59 · 95% CI -26.54 to 1.36
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -20.30 · 95% CI -33.85 to -6.75
SecondaryPercentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)2.7 (1.1 to 6.8)3.4 (1.5 to 7.7)14.4 (9.6 to 21.0)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.733 · Odds ratio (or): 1.24 · 95% CI 0.36 to 4.36
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.002 · Odds ratio (or): 5.42 · 95% CI 1.93 to 15.22
SecondaryPercentage of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS)

The Itch NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

Time frame:
16 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS)
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS)5.7 (2.8 to 11.3)15.9 (10.6 to 23.1)25.2 (18.5 to 33.3)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.012 · Odds ratio (or): 3.08 · 95% CI 1.29 to 7.36
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.32 · 95% CI 2.31 to 12.28
SecondaryChange From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)

Atopic Dermatitis Sleep Scale (ADSS) is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep, frequency of waking, and difficulty getting back to sleep last night. Item 2, frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)-0.40 ± 0.207-0.62 ± 0.177-0.99 ± 0.171
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.433 · Mean difference (final values): -0.21 · 95% CI -0.75 to 0.32
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.029 · Mean difference (final values): -0.59 · 95% CI -1.12 to -0.06
SecondaryChange From Baseline in Skin Pain NRS

Skin Pain NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Skin Pain NRS
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline in Skin Pain NRS-1.03 ± 0.342-2.16 ± 0.279-2.40 ± 0.266
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.012 · Mean difference (final values): -1.12 · 95% CI -1.99 to -0.25
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -1.36 · 95% CI -2.22 to -0.51
SecondaryPercentage of of Participants Achieving EASI50

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a ≥ 50% improvement from baseline in EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of of Participants Achieving EASI50
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of of Participants Achieving EASI5012.9 (8.4 to 19.3)19.7 (14.1 to 26.9)34.9 (27.7 to 43.0)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.105 · Odds ratio (or): 1.69 · 95% CI 0.90 to 3.20
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.67 · 95% CI 2.02 to 6.68
SecondaryPercentage of Participants Achieving IGA of 0

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA of 0
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving IGA of 00.7 (0.1 to 3.8)3.4 (1.5 to 7.7)2.7 (1.1 to 6.8)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.144 · Odds ratio (or): 3.81 · 95% CI 0.63 to 22.85
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.227 · Odds ratio (or): 3.10 · 95% CI 0.50 to 19.40
SecondaryChange From Baseline in SCORAD

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit and treatment-by-visit interaction as fixed categorial effects and baseline and baseline-by-visit interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in SCORAD
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline in SCORAD-14.37 ± 3.058-18.31 ± 2.445-26.18 ± 2.220
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.316 · Mean difference (final values): -3.94 · 95% CI -11.67 to 3.79
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -11.81 · 95% CI -19.23 to -4.40
SecondaryPercentage of Participants Achieving SCORAD90

The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. SCORAD90 is defined as a ≥ 90% improvement from baseline in the SCORAD score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SCORAD90
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving SCORAD901.4 (0.4 to 4.8)2.0 (0.7 to 5.8)3.4 (1.5 to 7.8)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.683 · Odds ratio (or): 1.39 · 95% CI 0.29 to 6.78
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.277 · Odds ratio (or): 2.25 · 95% CI 0.52 to 9.68
SecondaryChange From Baseline in Body Surface Area (BSA) Affected

Body surface area affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage of BSA
Change From Baseline in Body Surface Area (BSA) Affected
percentage of BSAPlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline in Body Surface Area (BSA) Affected-9.67 ± 2.352-15.69 ± 1.885-17.39 ± 1.746
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.046 · Mean difference (final values): -6.02 · 95% CI -11.93 to -0.12
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.009 · Mean difference (final values): -7.72 · 95% CI -13.46 to -1.98
SecondaryPercentage of Participants Developing Skin Infections Requiring Antibiotic Treatment

Percentage of participants developing skin infections requiring antibiotic treatment.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment5.54.14.1
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Fisher Exact · p = 0.598
  • Placebo vs 2 mg Baricitinib · Fisher Exact · p = 0.785
SecondaryPercent Change From Baseline in Itch NRS

The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA),and treatment-by-visit-interaction as fixed categorical effects and baseline, and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Itch NRS
percent changePlacebo1 mg Baricitinib2 mg Baricitinib
Percent Change From Baseline in Itch NRS-18.01 ± 5.133-30.28 ± 4.104-39.87 ± 3.904
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.063 · Mean difference (final values): -12.27 · 95% CI -25.21 to 0.66
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -21.85 · 95% CI -34.54 to -9.17
SecondaryChange From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)

The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)-2.67 ± 1.216-4.57 ± 0.937-7.44 ± 0.848
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.217 · Mean difference (final values): -1.90 · 95% CI -4.93 to 1.12
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -4.77 · 95% CI -7.70 to -1.84
SecondaryChange From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score

The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe." LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score-0.46 ± 0.139-0.71 ± 0.111-0.88 ± 0.105
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.155 · Mean difference (final values): -0.25 · 95% CI -0.60 to 0.10
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.017 · Mean difference (final values): -0.42 · 95% CI -0.76 to -0.07
SecondaryChange From Baseline on the Hospital Anxiety Depression Scale (HADS)

The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Hospital Anxiety Depression Scale (HADS)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Anxiety-2.03 ± 0.441-1.50 ± 0.356-2.55 ± 0.321
Depression-1.31 ± 0.362-0.87 ± 0.294-1.73 ± 0.263
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.345 · Mean difference (final values): 0.53 · 95% CI -0.58 to 1.65
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.336 · Mean difference (final values): -0.52 · 95% CI -1.59 to 0.55
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.353 · Mean difference (final values): 0.43 · 95% CI -0.48 to 1.35
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.340 · Mean difference (final values): -0.43 · 95% CI -1.31 to 0.45
SecondaryChange From Baseline on the Dermatology Life Quality Index (DLQI)

The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a little," "a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered or "not relevant" responses scored as "0." Scores range from 0 to 30 ("no impact on participant's life" to "extremely large effect on participant's life"), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS Means were calculated using a MMRM model with treatment, baseline disease severity (IGA),visit, and treatment-by-visit-interaction as fixed categorical and baseline, and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Dermatology Life Quality Index (DLQI)
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline on the Dermatology Life Quality Index (DLQI)-3.97 ± 0.959-5.47 ± 0.776-7.46 ± 0.695
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.224 · Mean difference (final values): -1.50 · 95% CI -3.92 to 0.92
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -3.50 · 95% CI -5.83 to -1.16
SecondaryChange From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire

The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. LS Mean were calculated using a MMRM model with treatment, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Absenteeism3.41 ± 4.7410.05 ± 3.6422.34 ± 3.078
Presenteeism-3.44 ± 4.037-15.18 ± 3.315-19.33 ± 2.990
Overall Work Impairment-0.88 ± 4.848-13.73 ± 3.943-17.15 ± 3.520
Activity Impairment-9.24 ± 3.334-18.87 ± 2.631-22.53 ± 2.401
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.575 · Mean difference (final values): -3.36 · 95% CI -15.30 to 8.57
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.851 · Mean difference (final values): -1.07 · 95% CI -12.43 to 10.30
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.026 · Mean difference (final values): -11.75 · 95% CI -22.05 to -1.45
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -15.90 · 95% CI -25.89 to -5.91
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.041 · Mean difference (final values): -12.85 · 95% CI -25.18 to -0.51
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.008 · Mean difference (final values): -16.27 · 95% CI -28.20 to -4.34
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.023 · Mean difference (final values): -9.64 · 95% CI -17.95 to -1.32
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.001 · Mean difference (final values): -13.29 · 95% CI -21.40 to -5.17
SecondaryChange From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Index Score United States (US) and United Kingdom (UK) Algorithm

The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the UK algorithm, with scores ranging from -0.594 to 1, and the US algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state. LS Means were calculated using a MMRM model with treatment, baseline disease activity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Index Score United States (US) and United Kingdom (UK) Algorithm
units on a scalePlacebo1 mg Baricitinib2 mg Baricitinib
Health State Index (US Algorithm)0.04 ± 0.0210.06 ± 0.0160.10 ± 0.015
Health State Index (UK Algorithm)0.07 ± 0.0290.09 ± 0.0230.14 ± 0.020
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.482 · Mean difference (final values): 0.02 · 95% CI -0.03 to 0.07
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.043 · Mean difference (final values): 0.05 · 95% CI 0.00 to 0.10
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.656 · Mean difference (final values): 0.02 · 95% CI -0.06 to 0.09
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.057 · Mean difference (final values): 0.07 · 95% CI -0.00 to 0.14
SecondaryChange From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)

EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranges from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine. LS Means were calculated using a MMRM model with treatment, baseline disease activity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interactions as fixed continuous effects.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · millimeters
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)
millimetersPlacebo1 mg Baricitinib2 mg Baricitinib
Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS)4.67 ± 2.0223.34 ± 1.6318.14 ± 1.497
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Mixed Models Analysis · p = 0.609 · Mean difference (final values): -1.33 · 95% CI -6.45 to 3.79
  • Placebo vs 2 mg Baricitinib · Mixed Models Analysis · p = 0.166 · Mean difference (final values): 3.48 · 95% CI -1.46 to 8.41
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement

The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement
percentage of participantsPlacebo1 mg Baricitinib2 mg Baricitinib
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement2.7 (1.1 to 6.8)5.4 (2.8 to 10.4)8.2 (4.8 to 12.8)
Statistical analysis
  • Placebo vs 1 mg Baricitinib · Regression, Logistic · p = 0.258 · Odds ratio (or): 1.96 · 95% CI 0.61 to 6.26
  • Placebo vs 2 mg Baricitinib · Regression, Logistic · p = 0.052 · Odds ratio (or): 2.99 · 95% CI 0.99 to 8.97

Adverse events

Collected over Baseline up to Week 104. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Period 1 WK 0 to 16)0/146 (0%)3/146 (2.1%)34/146 (23.3%)
1 Milligram (mg) Baricitinib (Period 1 WK 0 to 16)0/147 (0%)1/147 (0.7%)24/147 (16.3%)
2 mg Baricitinib (Period 1 WK 0 to 16)0/145 (0%)2/145 (1.4%)36/145 (24.8%)
Placebo (Period 2 WK 16 to 104)0/8 (0%)0/8 (0%)1/8 (12.5%)
1 mg Baricitinib (Period 2 WK 16 to 104)0/19 (0%)0/19 (0%)10/19 (52.6%)
2 mg Baricitinib (Period 2 WK 16 to 104)0/35 (0%)0/35 (0%)11/35 (31.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Period 1 WK 0 to 16)1 Milligram (mg) Baricitinib (Period 1 WK 0 to 16)2 mg Baricitinib (Period 1 WK 0 to 16)Placebo (Period 2 WK 16 to 104)1 mg Baricitinib (Period 2 WK 16 to 104)2 mg Baricitinib (Period 2 WK 16 to 104)
Hypertrophic cardiomyopathyCongenital, familial and genetic disorders0/1460/1471/1450/80/190/35
PneumoniaInfections and infestations0/1460/1471/1450/80/190/35
Respiratory tract infectionInfections and infestations0/1460/1471/1450/80/190/35
Hip fractureInjury, poisoning and procedural complications0/1460/1471/1450/80/190/35
BronchospasmRespiratory, thoracic and mediastinal disorders0/1460/1471/1450/80/190/35
Cholecystitis acuteHepatobiliary disorders1/1460/1470/1450/80/190/35
CellulitisInfections and infestations1/1460/1470/1450/80/190/35
DelusionPsychiatric disorders1/1460/1470/1450/80/190/35
HallucinationPsychiatric disorders1/1460/1470/1450/80/190/35
SeizureNervous system disorders0/1461/1470/1450/80/190/35
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlacebo (Period 1 WK 0 to 16)1 Milligram (mg) Baricitinib (Period 1 WK 0 to 16)2 mg Baricitinib (Period 1 WK 0 to 16)Placebo (Period 2 WK 16 to 104)1 mg Baricitinib (Period 2 WK 16 to 104)2 mg Baricitinib (Period 2 WK 16 to 104)
ImpetigoInfections and infestations3/1460/1471/1451/80/190/35
Upper respiratory tract infectionInfections and infestations9/1469/14710/1450/82/193/35
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/790/750/680/20/41/11
Urinary tract infectionInfections and infestations3/1461/1475/1450/80/193/35
NasopharyngitisInfections and infestations11/1463/1479/1450/81/190/35
Ovarian cyst rupturedReproductive system and breast disorders0/670/720/770/61/150/24
DiarrhoeaGastrointestinal disorders2/1463/1476/1450/80/192/35
Back painMusculoskeletal and connective tissue disorders1/1463/1470/1450/80/192/35
VomitingGastrointestinal disorders1/1460/1472/1450/81/190/35
Seasonal allergyImmune system disorders1/1461/1472/1450/81/190/35

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Placebo1 mg Baricitinib2 mg BaricitinibTotal
<=18 years0000
Between 18 and 65 years134134137405
>=65 years1313935
Sex: Female, Male
Sex: Female, Male(Participants)Placebo1 mg Baricitinib2 mg BaricitinibTotal
Female677277216
Male807569224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo1 mg Baricitinib2 mg BaricitinibTotal
American Indian or Alaska Native2226
Asian33262281
Native Hawaiian or Other Pacific Islander0022
Black or African American24263080
White808685251
More than one race76518
Unknown or Not Reported1102
Region of Enrollment
Region of Enrollment(Participants)Placebo1 mg Baricitinib2 mg BaricitinibTotal
Canada424037119
United States105107109321
08

Study locations

81 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Wallace Medical Group, Inc.
    Beverly Hills, California 90211, United States
  • California Dermatology and Clinical Research Institute
    Encinitas, California 92024, United States
  • Tien Q. Nguyen, MD inc. DBA First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Keck School of Medicine University of Southern California
    Los Angeles, California 90033, United States
  • University of California Davis-Dermatology
    Sacramento, California 95816, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Care Access Research-Walnut Creek
    Walnut Creek, California 94598, United States
  • Clinical Research Center of CT/NY
    Danbury, Connecticut 06810, United States
  • Univ of Connecticut
    Farmington, Connecticut 06032, United States
  • GWU/Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • Miami Dermatology & Laser Research
    Miami, Florida 33173, United States
  • Riverchase Dermatology and Cosmetic Surgery
    Pembroke Pines, Florida 33028, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Dermatologic Surgery Specialists, PC
    Macon, Georgia 31217, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Treasure Valley Dermatology
    Boise, Idaho 83713, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University Dermatology
    Darien, Illinois 60561, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Dermatology Specialist
    Louisville, Kentucky 40241, United States
  • Dermatology and Skin Cancer Specialists
    Rockville, Maryland 20850, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Skin Specialists, P.C
    Omaha, Nebraska 68144, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10003, United States
  • DermResearchCenter of New York, Inc
    Stony Brook, New York 11790, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Wright State Univ School of Medicine
    Fairborn, Ohio 45324, United States
  • Dermatologists of Southwest Ohio, Inc.
    Mason, Ohio 45040, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Dermatology & Laser Center of Charleston
    Charleston, South Carolina 29407, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Bellaire Dermatology
    Bellaire, Texas 77401, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Acclaim Dermatology, PLLC
    Sugar Land, Texas 77497, United States
  • University of Utah MidValley Dematology
    Murray, Utah 84107, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23502, United States
  • Multicare Health System
    Tacoma, Washington 98405, United States
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Institute for Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • Dr. Chih-ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Simcoderm Medical & Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P1X2, Canada
  • Allergy Research Canada Inc.
    Niagara Falls, Ontario L2H 1H5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • Medicor Research Inc
    Sudbury, Ontario P3C 1X8, Canada
  • K. Papp Clinical Research Inc
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Innovaderm Research Inc
    Montreal, Quebec H2K4L5, Canada
  • Centre de Recherche Dermatologique de Quebec Metropolitain
    Quebec, G1V 4X7, Canada
  • York Dermatology Center
    Richmond Hill, L4C 9M7, Canada
  • Office of Dr. Samuel Sanchez PSC
    Caguas, 00727, Puerto Rico
  • Office of Dr. Alma M. Cruz
    Carolina, 00985, Puerto Rico
  • Ponce School of Medicine CAIMED Center
    Ponce, 00716, Puerto Rico
  • GCM Medical Group PSC
    San Juan, 00917, Puerto Rico
09

References and documents

Publications

  • Simpson EL, Bissonnette R, Paller AS, King B, Silverberg JI, Reich K, Thyssen JP, Doll H, Sun L, DeLozier AM, Nunes FP, Eichenfield LF. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): a clinical outcome measure for the severity of atopic dermatitis. Br J Dermatol. 2022 Oct;187(4):531-538. doi: 10.1111/bjd.21615. Epub 2022 Aug 21. PubMed 35442530 ↗
  • Rosmarin D, Casillas M, Chen S, Dawson Z, Pierce E, Zhang H, Bukhalo M, Smith S. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5). J Cutan Med Surg. 2022 May-Jun;26(3):262-266. doi: 10.1177/12034754211073661. Epub 2022 Jan 28. PubMed 35086348 ↗
  • Silverberg JI, Boguniewicz M, Waibel J, Weisman J, Strowd L, Sun L, Ding Y, Feely M, Nunes FP, Simpson EL. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16. Dermatol Ther (Heidelb). 2022 Jan;12(1):137-148. doi: 10.1007/s13555-021-00640-7. Epub 2021 Nov 30. PubMed 34846636 ↗
  • Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021 Oct 23;19(1):247. doi: 10.1186/s12955-021-01877-8. PubMed 34688290 ↗
  • King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. PubMed 33826132 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2019, 21 months.

Results were first posted in Jan 2021, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 21 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2018
First posted
Feb 15, 2018
StartActual
Feb 20, 2018
Primary completionActual
Dec 9, 2019
CompletionActual
Aug 16, 2021
Results first posted
Jan 25, 2021
Last update
Sep 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03435081
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
Feb 20, 2018
Primary completion
Dec 9, 2019
Completion
Aug 16, 2021
Results posted
Jan 25, 2021
Last update
Sep 9, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion